IL28 (Interleukin-28A, IL-28A, Interferon lambda-2, IFN-lambda-2, Cytokine ZCYTO20, IFNL2, ZCYTO20, IL28A)

Antibodies / Antibodies-Interleukin

-20°C

Supplied as a lyophilized powder in PBS, trehalose. Reconstitute with 200ul sterile PBS.

Recombinant corresponding to aa20-193 from IL-28A/IFN-l2 expressed in NSO cells (NP_001019844).

IL-28A are type III interferons that are class II cytokine receptor ligands (1-4). They are distantly related to members of the IL-10 family and type I IFN family (1-4). Mouse IL-28A cDNA encodes a 193aa protein with a 19aa signal peptide and a 174aa mature protein that lacks N-glycosylation sites. Mature mouse IL-28A shares 81% and 66% aa sequence identity with rat and human IL-28A, respectively, and functions across species (5). Mouse IL-28A and IL-28B share 97% aa identity; the mouse lacks a functional IL-29 gene (4). Type III interferons are widely expressed, but are mainly produced by antigen presenting cells in response to viruses and double-stranded RNA that interact with Toll-like receptors or RIG-1 family helicases (2 - 6). They signal through a widely expressed receptor that is a heterodimer of the IL-10 receptor b (IL-10 Rb) and IL-28 receptor a (IL-28 Ra; also called IFN-l R1) (2, 3, 7, 9). Interaction of either type I or type III IFNs with their receptors activates similar pathways, including JAK tyrosine kinase activation, STAT phosphorylation and formation of the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex (1-3). Both type I and III IFNs induce antiviral activity and upregulate MHC class I antigen expression (2-6). Cell lines responsive to type III IFNs are also responsive to type I IFNs, but in general, higher concentrations of type III IFNs are needed for similar in vitro responses (8). In vivo, however, type III IFNs enhance levels of IFN-g in serum, suggesting that the robust antiviral activity of type III IFNs may stem in part from activation of the immune system (5, 7). Anti-proliferative and antitumor activity in vivo has also been shown for type III IFNs (9-11).

Applications:
Suitable for use in Neutralization. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.